Research programme: protozoan infection and tuberculosis therapeutics - Broad Institute/Eisai

Drug Profile

Research programme: protozoan infection and tuberculosis therapeutics - Broad Institute/Eisai

Alternative Names: Chagas disease therapeutics - Broad Institute/Eisai; Malaria therapeutics - Broad Institute/Eisai; Protein synthesis inhibitors - Broad Institute/Eisai

Latest Information Update: 08 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Broad Institute; Eisai Co Ltd
  • Class Antimalarials; Antiprotozoals; Antituberculars; Small molecules
  • Mechanism of Action Amino acyl tRNA synthetase inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Chagas disease; Malaria; Protozoan infections; Tuberculosis

Most Recent Events

  • 22 May 2017 Eisai and the Broad Institute agree to co-develop antimalarial compounds for Malaria
  • 19 Sep 2014 Eisai and Broad Institute receive grant from Global Health Innovative Technology Fund for drug development in Malaria
  • 16 Sep 2014 Eisai and Broad Institute enter into agreement to identify novel therapeutic for the treatment of Malaria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top